首页> 美国卫生研究院文献>other >Automated cassette-based production of high specific activity 203/212pb peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer
【2h】

Automated cassette-based production of high specific activity 203/212pb peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer

机译:基于盒式自动生产高比活性203 / 212pb肽的治疗性放射性药物用于图像指导的放射性核素治疗癌症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides. Radiolabeling was found to proceed efficiently at 85 °C (45 min; pH 5.5). The specific activity of radiolabeled conjugates was optimized by separation of radiolabeled conjugates from unlabeled peptide via HPLC. Preservation of bioactivity was confirmed by in vivo biodistribution of Pb-203 and Pb-212 labeled peptides in melanoma-tumor-bearing mice. The approach has been found to be robustly adaptable to automation and a cassette-based fluid-handling system (Modular Lab Pharm Tracer) has been customized for clinical radiopharmaceutical production. Our findings demonstrate that the Pb-203/Pb-212 combination is a promising elementally-matched radionuclide pair for image-guided radionuclide therapy for melanoma, neuroendocrine tumors, and potentially other cancers.
机译:已经开发了一种用于癌症成像和放射性核素治疗的Pb-212和Pb-203标记的螯合剂修饰的基于肽的放射性药物的制备方法,并已用于自动临床生产。使用填充在一次性塑料柱中的市售Pb专用色谱树脂,可以优化从稀盐酸中干扰金属中放射性Pb2 +的预浓缩和分离。将预浓缩的放射性Pb2 +在NaOAc缓冲液中直接洗脱到含有螯合剂修饰的肽的反应容器中。发现放射性标记在85°C(45分钟; pH 5.5)下有效进行。通过经由HPLC将放射性标记的缀合物与未标记的肽分离来优化放射性标记的缀合物的比活性。通过在患有黑素瘤的小鼠中体内Pb-203和Pb-212标记的肽的体内生物分布来确认生物活性的保存。已经发现该方法非常适合自动化,并且已经为临床放射性药物生产定制了基于盒的流体处理系统(Modular Lab Pharm Tracer)。我们的发现表明,Pb-203 / Pb-212组合是一种有前途的元素匹配放射性核素对,可用于黑色素瘤,神经内分泌肿瘤和其他潜在癌症的图像引导放射性核素治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号